Germans chase drug

A small Sydney-based company, with widespread WA distribution of its mostly pharmaceutical products, has achieved an international breakthrough with a new technology.

One of these, Gradiflow – an apparatus for purifying protein in development of cancer fighting drugs – is believed to have great potential.

Gradipore has commercialised its technology base with a significant distribution research and development deal with Eppendorf-Netheler-Hinz GmbH (Eppendorf), a well-known and well-respected private German life science company with turnover of US$220 million per annum.

Two of Gradipore’s three technologies – the Gradigels and Gradiflow – are the subject of the Eppendorf agreement.